PPT-Module 9: HER2-Positive and

TripleNegative Breast Cancer Jamie Carroll APRN MSN CNP Hope S Rugo MD Disclosures for Ms Carroll No financial interests or affiliations to disclose Disclosures for Dr Rugo Contracted Research. . Raouf E. Nakhleh, MD. Mayo Clinic Florida. Disclosure Information. Raouf E Nakhleh, MD. I have no financial relationships to disclose. Objectives. . Discuss evidence based guideline development and their impact on the future from a QA perspective. Clinical Practice Guideline Update. American Society of Clinical Oncology /. College of American Pathologists . www.asco.org/guidelines/. © American . Society of Clinical Oncology®.  All rights reserved.. Gradishar. . MD, FACP. Betsy . Bramsen. Professor of Breast Oncology. Director, Maggie Daley Center For Women's Cancer Care. Robert H. Lurie Comprehensive Cancer Center. Northwestern University Feinberg School of Medicine. ASCO-CAP Recommendations For HER2 Testing in Breast Cancer. Criteria For Reporting HER2 Test Results . as Positive. Criteria for Reporting HER2 Test Results . as Negative. Criteria for Reporting Equivocal Results . Mohammad . Jahanzeb. , MD, FACP. Professor of Clinical Medicine, Hematology-Oncology. Director, UM Sylvester Deerfield Campus. Associate Center Director for Community Outreach. Sylvester Comprehensive Cancer Center. Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings Christy A Russell, MD Keck School of Medicine University of Southern California Metastatic Breast Cancer Heather M. Gage, MD, Avanti . Rangnekar. , Robert E. Heidel, . PhD. , Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, . PhD. The Graduate School of Medicine. The Department of Pathology. Introduction. A. University of Tennessee Medical Center – Knoxville. Departments of Pathology, Surgery, and Medicine. BREAST CANCER IN YOUNG AGE (≤40 YEARS): THE UNIVERSITY OF. . TENNESSEE MEDICAL CENTER AT KNOXVILLE 10 YEAR EXPERIENCE. Biodegradable . nanobrushes. for drug delivery. . . Eggehard . Holler, Hui Ding, . Ramachandran Murali, Julia Y. Ljubimova . Cedars-Sinai Medical . Cen. ter. ,. . Los. . Angeles. , U. SA. Drug. SentinelLymphNodeBiopsyAfterNeoadjuvantChemotherapy inPatientswithCytologicallyProvenNode-positiveBreastCancer atDiagnosis SehoPark,MD 1 ,JiMinPark,MD 1 ,JungHoonCho,MD 1 ,HyungSeokPark,MD 1 ,SeungIlK s. mall Cell . Lung Cancer. , Gastric Cancer, and Colorectal Cancer. H. Jack West, MD. Associate Clinical Professor in Medical Oncology. City of Hope Comprehensive Cancer Center. Duarte, CA. Suresh S. Ramalingam, MD, FACP, FASCO. Senior Investigator, . Breast Cancer Research. Tennessee Oncology, PLLC. Nashville, Tennessee. Key Ongoing Clinical Trials in HR-Positive/HER2-Negative Early-Stage Breast Cancer. This program is supported by educational grants from AstraZeneca, Lilly and Merck Sharp & Dohme Corp.. Breast Cancer . Elizabeth O’Reilly, MSN, MPH, ANP-BC. Sara . Hurvitz. , MD. Disclosures for . Ms. O’Reilly. No financial interests or affiliations to disclose. Disclosures for Dr . Hurvitz. Salary: . ishtiaq. . FCPS R3 general surgery unit one UKSO . prof . tariq. . ghaffor. . sb. . . Objectives. Surgical Anatomy. Investigations. Diagnosis.